Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravagalimab (ABBV-323) in Ulcerative Colitis
NCT03695185Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of ravagalimab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Mar 2019; status: completed.
02
Drugs
ravagalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03695185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695185.